Wednesday, 15 February 2017
On 2/15/2017 10:54:00 am by Suhani Varma in Accurate Stock Tips, best intraday tips provider, best stock tips, Equity Tips, Indian stock tips, intraday tips, Premium Equity Tips, Share advisory, Shares Tips, Stock Option, ways2cap Premium Equity Tips No comments

Vivimed Labs's consolidated revenue for the quarter came in at Rs. 363 crore, registering 9.3% yoy increase. This was primarily driven by 19% yoy increase in revenue from Pharma business which accounts for 80% of company’s business.
EBITDA for the quarter rose by 68.3% yoy to Rs. 103.5 crore with a corresponding margin expansion of 999 bps. EBITDA margin for the quarter stood at 28.5%. This margin expansion was aided by 8% yoy decrease in cost of materials consumed and changes in inventories.
The PAT for the quarter came in at Rs. 51.7 crore, yoy increase of 124.8%. This was partly due to 9.8% yoy decline in finance costs.
Vivimed Labs posted Q3FY17 consolidated results on February 14.
Vivimed Labs Ltd is currently trading at Rs. 104.25, up by 7.25 points or 7.47% from its previous closing of Rs. 97 on the BSE. The scrip opened at Rs. 110 and has touched a high and low of Rs. 110.5 and Rs. 102.2 respectively. So far 3279963(NSE+BSE) shares were traded on the counter. The stock is currently trading below its 100 DMA.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment